Indications for: ULTANE

Induction and maintenance of general anesthesia for surgery.

Adults and Children:

Use sevoflurane calibrated vaporizer. Individualize. Surgical maintenance: usually 0.5–3% sevoflurane with or without nitrous oxide. May be administered with any type of anesthesia circuit. See full labeling for minimum alveolar concentration (MAC) values based on age.

ULTANE Contraindications:

Genetic susceptibility to malignant hyperthermia. Sensitivity to halogenated agents.

ULTANE Warnings/Precautions:

To be administered only by those experienced in general anesthesia. Have intubation, artificial ventilation, oxygen and circulatory resuscitation available. Sevoflurane exposure >2 MAC hours at flow rates 1 to <2L/min and fresh gas flow rates <1L/min: not recommended. Renal insufficiency. Severe hepatic impairment. Monitor BP, HR, ECG, hepatic and renal function, respiration, urine flow during treatment. Susceptible to congenital long QT syndrome. Risk of malignant hyperthermia; discontinue all triggering agents if suspected (eg, volatile anesthetic agents, succinylcholine). Neuromuscular disease (eg, Duchenne muscular dystrophy). Desiccated CO2 absorbents. Pediatric neurotoxicity risk with repeated or prolonged use. Bradycardia in pediatrics with Down syndrome. Elderly. Premature infants. Labor & delivery. Pregnancy. Nursing mothers.

ULTANE Classification:

Inhalation anesthetic.

ULTANE Interactions:

Concomitant KOH containing CO2 absorbents: not recommended. Risk of ventricular arrhythmias with epinephrine. Hyperkalemia with succinylcholine. Marked hypotension with calcium antagonists. Increased risk of hemodynamic instability during surgical/medical procedures with MAO inhibitors. Potentiated by benzodiazepines, opioids, nitrous oxide. Potentiates neuromuscular blockers (eg, pancuronium, vecuronium, atracurium). Caution with concomitant drugs that prolong the QT interval.

Adverse Reactions:

Nausea, vomiting, agitation, somnolence, dizziness, increased salivation, tachycardia, bradycardia, hypotension, cough increased, laryngospasm, airway obstruction, breath holding, shivering, apnea, hypertension; perioperative hyperkalemia, renal injury (eg, glycosuria and proteinuria); rare: seizures (esp. children), post-op hepatic dysfunction, hepatitis, torsades de pointes, transient elevations in glucose, LFTs, WBC count.


Hepatic (CYP2E1).

Drug Elimination:

Renal (minor).

Generic Drug Availability:


How Supplied:

Bottle (250mL)—1